KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Aquestive Therapeutics (AQST) over the last 6 years, with Q3 2025 value amounting to -$1.3 million.

  • Aquestive Therapeutics' Change in Account Payables fell 16961.62% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 41583.51%. This contributed to the annual value of $2.8 million for FY2024, which is 37274.51% up from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Change in Account Payables is -$1.3 million, which was down 16961.62% from -$323000.0 recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Change in Account Payables high stood at $2.6 million for Q4 2024, and its period low was -$3.0 million during Q2 2024.
  • Its 5-year average for Change in Account Payables is $257684.2, with a median of $182000.0 in 2022.
  • In the last 5 years, Aquestive Therapeutics' Change in Account Payables tumbled by 104723.62% in 2021 and then surged by 127032.97% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Change in Account Payables (Quarter) stood at $2.1 million in 2021, then plummeted by 153.6% to -$1.1 million in 2022, then rose by 5.07% to -$1.1 million in 2023, then surged by 346.82% to $2.6 million in 2024, then plummeted by 149.54% to -$1.3 million in 2025.
  • Its Change in Account Payables stands at -$1.3 million for Q3 2025, versus -$323000.0 for Q2 2025 and $1.9 million for Q1 2025.